Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences’ Lead Medicine into Advanced Clinical Trials

by Virtus | Jul 2, 2025

LONDON – VirTus Respiratory Research Ltd, a leading respiratory-focused contract research organisation (CRO), today announced that results from their human rhinovirus challenge model in patients with chronic obstructive pulmonary disease (COPD) provided Altesa...

Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations.

by Virtus | Dec 6, 2019

Click the button below to read more about this.

Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation.

by Virtus | Dec 6, 2019

Click the button below to read more about this.

Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations.

by Virtus | Nov 6, 2019

Click the button below to read more about this.

Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production.

by Virtus | Nov 3, 2019

Click the button below to read more about this.